Table 2

Bronchodilatory assessments (trough FVC, peak FEV₁ and standardised FEV₁ AUC and trough IC) at days 1 and 7 (mITT population)

	QVA149 300/50 μg	Indacaterol 300 μg	Indacaterol 600 μg	Placebo
	N=142	N=140	N=142	N=140
Least squares mean (SE)
Day 1
Trough FVC (l)	3.316 (0.021)^*	2.964 (0.021)	2.978 (0.021)	2.873 (0.021)
Peak FEV₁	1.659 (0.014)^*	1.567 (0.015)	1.559 (0.014)	1.423 (0.015)
Standardised FEV₁ AUC_5min-4h	1.576 (0.013)^*	1.487 (0.014)	1.490 (0.013)	1.345 (0.014)
Standardised FEV₁ AUC_{5min–23h 45min}	1.548 (0.012)^*	1.440 (0.012)	1.444 (0.012)	1.330 (0.012)
Trough IC (l)	2.180 (0.019)^* ^†	2.092 (0.019)	2.102 (0.019)	2.029 (0.019)

Day 7
Trough FVC (l)	3.148 (0.023)^*	2.956 (0.024)	2.968 (0.023)	2.819 (0.024)
Peak FEV₁	1.709 (0.020)^*	1.579 (0.020)	1.573 (0.020)	1.394 (0.020)
Standardised FEV₁ AUC_5min–4h	1.641 (0.019)^*	1.505 (0.019)	1.495 (0.019)	1.320 (0.019)
Standardised FEV₁ AUC_5min–12h	1.610 (0.018)^*	1.473 (0.018)	1.457 (0.018)	1.317 (0.018)
Standardised FEV₁ AUC_{5min–23h 45 min}	1.569 (0.016)^*	1.438 (0.017)	1.427 (0.017)	1.302 (0.017)
Trough IC (l)	2.191 (0.021)^*	2.090 (0.022)	2.073 (0.022)	1.973 (0.022)

↵* p<0.0001 for QVA149 300/50 μg versus placebo, indacaterol 300 μg and indacaterol 600 μg.
↵† p<0.01 for QVA149 300/50 μg versus indacaterol 300 μg and indacaterol 600 μg.
AUC, area under the curve; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacityl; IC, inspiratory capacity; mITT, modified intent-to-treat.